Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 9/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 0.76 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.71 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.68 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.68 |
| ▸ | PPARA | Q07869 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.63 |
| ▸ | HPD | P32754 | 1/20 | 0.63 |
| ▸ | RXRA | P19793 | 1/20 | 0.61 |
| ▸ | RXRB | P28702 | 1/20 | 0.61 |
| ▸ | RXRG | P48443 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30994900 | 0.88 | NR4A2 (0.82) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL27815839 | 0.88 | NR4A2 (0.82) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL30207018 | 0.87 | NR4A2 (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL339009 | 0.87 | NR4A2 (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL4640232 | 0.87 | NR4A2 (0.76) | NR4A2MAOBMRGPRX4KMT2AHPD | |
| SCHEMBL1123155 | 0.86 | NR4A2 (0.91) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| Hydrochloric Acid SCHEMBL4748074 | 0.86 | NR4A2 (0.97) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL7052037 | 0.85 | NR4A2 (1.00) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL7221881 | 0.85 | MAOB (0.78) | NR4A2MAOBMRGPRX4NR4A1NR4A3 | |
| SCHEMBL1122713 | 0.84 | NR4A2 (0.94) | NR4A2MAOBMRGPRX4NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | disclosed |
| US-8809540-B2 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | disclosed |
| CN-101679217-A | N-adamantyl benzamides as 11 beta-hydroxysteroid dehydrogenase inhibitors | HIGH POINT PHARMACEUTICALS LLC | 2010-03-24 | — | — | CN | disclosed |
| EP-2150526-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008101914-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| US-3764702-A | TREATMENT OF THROMBOSIS | SCIENCE UNION & CIE | 1973-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | NR4A2 969/4885MAOB 721/4885MRGPRX4 3754/4885 |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | NR4A2 1878/4885MAOB 1487/4885MRGPRX4 3555/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | NR4A2 679/4885MAOB 1871/4885MRGPRX4 4239/4885 |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | NR4A2 1878/4885MAOB 1487/4885MRGPRX4 3555/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | NR4A2 679/4885MAOB 1871/4885MRGPRX4 4239/4885 |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | NR4A2 1878/4885MAOB 1487/4885MRGPRX4 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.